IRLAB Therapeutics (IRLAB) ABGSC Investor Days summary

Strategic focus and business model

• Aims to address all stages and symptoms of Parkinson's disease, as well as other CNS disorders, using a proprietary Integrative Screening Process (ISP) platform for drug discovery.

• Platform leverages AI and machine learning, resulting in higher success rates (20% from preclinical to phase III) and lower costs compared to industry standards (7%).

• Business model centers on developing candidates to proof of concept (typically phase II), then seeking partners for further development, commercialization, and revenue via upfront payments, milestones, and royalties.

• Strong patent protection for pipeline assets, with exclusivity extending into the early 2040s.

Pipeline and clinical development

• Lead candidate mesdopetam is phase III-ready for levodopa-induced dyskinesia, with plans to expand into psychosis; phase III program designed with regulatory and market input.

• Pirepemat is in phase II for balance and falls, with data expected end of Q1 next year; significant pharma interest for partnering.

• IRL757 targets apathy in Parkinson's and Alzheimer's, with ongoing phase I studies and a collaboration with MSRD Otsuka covering development to proof of concept.

• Two preclinical assets, IRL942 (cognitive impairment) and IRL1117 (next-generation Parkinson's therapy), are planned to enter clinical phase next year.

Financial and partnering outlook

• Actively seeking partners for mesdopetam and pirepemat, with business development ongoing and high interest from big pharma.

• Partnering timelines are uncertain due to a slower deal environment in 2024; deals may take a year or more.

• Financing options, including bridge financing, are under consideration and depend on progress with mesdopetam partnering.

• Prefers to have a partner for phase III mesdopetam to support both funding and commercialization.